September 22, 2023 Sophia Vida
Breaking News

SELLAS SLS009 Phase 1 Clinical Study Successfully Achieves All Primary and Secondary Endpoints

September 22, 2023 Late-stage biopharmaceutical company, SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) has announced positive topline data for the patient group with relapsed/refractory (r/r) lymphomas from its Phase 1 dose-escalation trial of its CDK9 inhibitor, SLS009 (GFH009). “We are excited to share strong topline data from the Phase 1 trial of SLS009 in lymphoma patients. The … Continue reading “SELLAS SLS009 Phase 1 Clinical Study Successfully Achieves All Primary and Secondary Endpoints”